Thông tin tài liệu
Thông tin siêu dữ liệu biểu ghi
Trường DC | Giá trị | Ngôn ngữ |
---|---|---|
dc.contributor.author | Ejeh, Stephen | vi |
dc.contributor.other | Uzairu, Adamu | vi |
dc.contributor.other | Shallangwa, Gideon A. | vi |
dc.contributor.other | Abechi, Stephen E. | vi |
dc.contributor.other | Ibrahim, Muhammad Tukur | vi |
dc.date.accessioned | 2023-03-29T09:22:47Z | - |
dc.date.available | 2023-03-29T09:22:47Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 2522-8307 | vi |
dc.identifier.uri | http://tailieuso.tlu.edu.vn/handle/DHTL/12739 | - |
dc.description.abstract | Hepatitis C virus (HCV) is a contagious disease that damages the liver over time, eventually leading to cirrhosis and death. Chronic HCV infection is regarded as a serious health problem worldwide, impacting up to 3% of the populace and killing over 300,000 people annually. Quick reproduction driven by non-structural protein 5B (NS5B), which is a possible target spot for the development of anti-HCV vaccines, causes genomic diversity. Sofosbuvir, a new oral NS5B inhibitor, was recently licensed by the US Food and Drug Administration for the cure of HCV. Unfortunately, it has received a lot of attention due to its financial concerns and adverse effects. As a result, there is a pressing need to explore alternative HCV treatments that are both cost-effective and free of adverse effects. In this study, we used a Pharmacoinformatics-based strategy to identify and design bioactive molecules that are anti-HCV NS5B. The simulation outcomes are compared to Sofosbuvir simulation outcomes. | vi |
dc.description.uri | https://link.springer.com/article/10.1186/s42269-022-00796-y | vi |
dc.language | en_US | vi |
dc.relation.ispartofseries | Bulletin of the National Research Centre, Volume 46 (2022), Article number: 109 | vi |
dc.subject | In silico design | vi |
dc.subject | NS5B inhibitors | vi |
dc.subject | Pharmacoinformatics approach | vi |
dc.subject | Drug discovering | vi |
dc.title | In silico design and pharmacokinetics investigation of some novel hepatitis C virus NS5B inhibitors: pharmacoinformatics approach | vi |
dc.type | BB | vi |
Trong bộ sưu tập: | Tài liệu mở |
Danh sách tệp tin đính kèm:
Hiện tại không có tệp tin đính kèm tới tài liệu.
Bạn đọc là cán bộ, giáo viên, sinh viên của Trường Đại học Thuỷ Lợi cần đăng nhập để Xem trực tuyến/Tải về
Khi sử dụng tài liệu trong thư viện số bạn đọc phải tuân thủ đầy đủ luật bản quyền.